A review of the use of activation markers in Africa

Journal of HIV Therapy

Volumn 15, Issue 1, 2010, Pages 11-14

  John, Laurence ^a   Lutwama, Fred ^b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CD38 ANTIGEN; HLA DR ANTIGEN;

AFRICA; CD8+ T LYMPHOCYTE; DRUG RESPONSE; ENDEMIC DISEASE; HELMINTHIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; MALARIA; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUBERCULOSIS; VIRUS LOAD;

AFRICA; ANTIGENS, CD; BIOLOGICAL MARKERS; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 77953297454     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS, 2008, 22, 439-446.
2. Doisne JM, Urrutia A, Lacabaratz-Porret C et al. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol, 2004, 173, 2410-2418.
3. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006, 12, 1365-1371.
4. Bentwich Z, Maartens G, Torten D et al. Concurrent infections and HIV pathogenesis. AIDS, 2000, 14, 2071-2081.
5. Fauci A. Immunopathogenic mechanisms of human immunodeficiency virus disease: implications for therapy. Am J Med, 1995, 99 (6A), 59S-60S.
6. UNAIDS. AIDS Epidemic Update 2009. Available at: www.unaids. org1en1Publications1default.asp (last accessed 30 March 2010).
7. Anzala OA, Nagelkerke NJ, Bwayo JJ et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis, 1995, 171, 686-689.
8. Lawn SD. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J Infect, 2004, 48, 1-12.
9. Giorgi JV. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up (The Los Angeles Center, Multicenter AIDS Cohort Study). J Acquir Immune Defic Syndr, 1993, 6, 904-912.
10. Borkow G, Bentwich Z. HIV and helminth co-infection: is deworming necessary? Parasite Immunol, 2006, 28, 605-612.
11. Rizzardini G, Piconi S, Ruzzante S et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS, 1996, 10, 1535-1542.
12. Messele T, Abdulkadir M, Fontanet AL et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol, 1999, 115, 443-450.
13. Kassu A, Tsegaye A, Wolday D et al. Role of incidental and1or cured intestinal parasitic infections on profile of CD4+ and CD8+ T cell subsets and activation status in HIV-1 infected and uninfected adult Ethiopians. Clin Exp Immunol, 2003, 132, 113-119.
14. Brown M, Kizza M, Watera C et al. Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis, 2004, 190, 1869-1879.
15. Wolday D, Mayaan S, Mariam ZG et al. Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr, 2002, 31, 56-62.
16. Hertoghe T, Wajja A, Ntambi L et al. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol, 2000, 122, 350-357.
17. Goletti D, Weissman D, Jackson RW et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol, 1996, 157, 1271-1278.
18. Whalen CC, Nsubuga P, Okwera A et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS, 2000, 14, 1219-1228.
19. Eggena MP, Hopkins H, Barugahare B et al. CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria. Am J Trop Med Hyg, 2006, 74, 41-43.
20. Kublin JG, Patnaik P, Jere CS et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet, 2005, 365, 233-240.
21. Pisell TL, Hoffman IF, Jere CS et al. Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection. AIDS, 2002, 16, 1503-1509.
22. Kerlikowske KM, Katz MH, Allen S et al. Beta 2-microglobulin as a predictor of death in HIV-infected women from Kigali, Rwanda. AIDS, 1994, 7, 963-969.
23. Jaffar S, Van der Loeff MS, Eugen-Olsen J et al. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. AIDS Res Hum Retroviruses, 2005, 6, 560-564.
24. Drain PK, Kupka R, Msamanga GI et al. C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS, 2007, 21, 2067-2075.
25. Baeten JM, Chohan B, Lavreys L et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis, 2007, 195, 1177-1180.
26. Vasan A, Renjifo B, Hertzmark E et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis, 2006, 42, 843-852.
27. Bousheri S, Burke C, Ssewanyana I et al. Infection with different hiv subtypes is associated with CD4 activation-associated dysfunction and apoptosis. J Acquir Immune Defic Syndr, 2009, 52, 548-552.
28. Sherman GG, Scott LE, Galpin JS et al. CD38 expression on CD8(+) T cells as a prognostic marker in vertically HIV-infected pediatric patients. Pediatr Res, 2002, 51, 740-745.
29. Morgan D, Mahe C, Mayanja B et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS, 2002, 16, 597-603.
30. Jaffar S, Grant AD, Whitworth J et al. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ, 2004, 6, 462-469.
31. Liu Z, Cumberland WG, Hultin LE et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol, 1998, 18, 332-340.
32. Coetzee LM, Tay SS, Lawrie D et al. From research tool to routine test: CD38 monitoring in HIV patients. Cytometry B Clin Cytom, 2009, 76, 375-384.
33. Liu Q, Kriksunov IA, Graeff R et al. Crystal structure of human CD38 extracellular domain. Structure, 2005, 13, 1331-1339.
34. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T cell activation or an active player in virus1host interactions? AIDS, 2000, 14, 1079-1089.
35. Zidovec LS, Vince A, Dakovic RO et al. Increased numbers of CD38 molecules on bright CD8+ T lymphocytes in infectious mononucleosis caused by Epstein-Barr virus infection. Clin Exp Immunol, 2003, 133, 384-390.
36. Liu Z, Cumberland WG, Hultin LE et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 16, 83-92.
37. Bisset LR, Cone RW, Huber W et al. Highly active antiretroviral therapy during early HIV infection reverses T cell activation and maturation abnormalities (Swiss HIV Cohort Study). AIDS, 1998, 12, 2115-2123.
38. Bouscarat F, Levacher M, Landman R et al. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS, 1998, 12, 1267-1273.
39. Giorgi JV, Majchrowicz MA, Johnson TD et al. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS, 1998, 12, 1833-1844.
40. Giorgi JV, Detels R. T cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol, 1989, 52, 10-18.
41. Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses, 1998, 14, 561-569.
42. Messele T, Abdulkadir M, Fontanet AL et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol, 1999, 115, 443-450.
43. Eggena MP, Barugahare B, Okello M et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis, 2005, 191, 694-701.
44. Koblavi-Deme S, Maran M, Kabran N et al. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy. AIDS, 2003, 17 Suppl 3, S17-S22.
45. Ondoa P, Koblavi-Deme S, Borget MY et al. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cote d'Ivoire. Clin Exp Immunol, 2005, 140, 138-148.
46. Schmitz JL, Czerniewski MA, Edinger M et al. Multisite comparison of methods for the quantitation of the surface expression of CD38 on CD8(+) T lymphocytes (The ACTG Advanced Flow Cytometry Focus Group). Cytometry, 2000, 42, 174-179.
47. Ondoa P, Dieye TN, Vereecken C et al. Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal. J Acquir Immune Defic Syndr, 2006, 41, 416-424.
48. Eller MA, Lutwama F, John L et al. CD38 expression on CD8 T cells with or without other markers (HLA DR and CD45RA) is not adequate to predict the virological response to antiretroviral therapy (ART) in Ugandans: XVI International AIDS Conference Toronto (Abstr. MOPE0110). 2006. Available at: www.iasociety.org1Default.aspx?pageId=11&abstractId=2192653 (last accessed 30 March 2010).
49. Glencross DK, Janossy G, Coetzee LM et al. CD81CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom, 2008, 74 Suppl 1, S131-S140.
50. Colebunders R, John L, Huyst V et al. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis, 2006, 10, 946-953.
51. Meintjes G, Wilkinson KA, Rangaka MX et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med, 2008, 178, 1083-1089.